Stock of the Day

Edwards Lifesciences (EW)

$88.05

+$1.60 (+1.8%)

Market Cap: $49.78B

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

• Edwards Lifesciences Co. recently received FDA approval for its AUTUS size-adjustable pulmonary valve for pediatric patients, a development that expands the company's product portfolio into a new therapeutic area and demonstrates its continued innovation in structural heart disease treatments.
• The company reported strong financial performance in its most recent quarter, with revenue of $1.74 billion, which exceeded the consensus estimate of $1.70 billion and represented a 13.6% year-over-year increase, indicating robust demand for its medical technologies.
• Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of Moderate Buy and a target price of $100.27, which suggests potential upside from the current stock price of $88.05 as of October 15, 2026.
• Edwards Lifesciences Co. has a low debt-to-equity ratio of 0.06, reflecting a strong balance sheet and financial stability that can support long-term growth initiatives and provide a buffer against economic downturns.
• The company is scheduled to host an investor event on November 2, 2026, including a live Q&A with physicians and management, which may provide additional insights into its strategic direction and product pipeline, potentially boosting investor confidence.

Edwards Lifesciences Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

• Insiders have been consistently selling shares, with 24 sales and no purchases in the past six months, including recent transactions by executives such as VP Daniel Lippis and SVP Andrew M. Dahl, which may signal a lack of confidence in the stock's near-term performance.
• Several institutional investors, including Ninety One UK Ltd and Ninety One North America Inc., have reduced their positions in Edwards Lifesciences Co. during the third quarter, with Ninety One UK Ltd selling 393,827 shares and Ninety One North America Inc. decreasing its stake by 5.6%, indicating potential institutional skepticism.
• The stock's price-to-earnings ratio of 30.76 is relatively high compared to some peers, which may limit upside potential if earnings growth does not accelerate to justify the valuation, especially given the company's guidance for FY 2026 EPS of $2.950 to $3.050.
• Short interest in Edwards Lifesciences Co. has increased slightly, with 9,538,735 shares shorted as of September 30, 2026, representing a 4.96% month-to-month increase, which could indicate bearish sentiment among some market participants.
• The company's dividend yield is 0.00%, meaning it does not provide income to investors, which may be a drawback for those seeking regular cash flow from their investments, particularly in a market where dividend-paying stocks are often favored for stability.

Recent News

• Edwards Lifesciences Earnings Preview: What to Expect (barchart.com)
• Edwards Lifesciences (NYSE:EW) VP Sells $53,017.35 in Stock (insidertrades.com)